<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03357731</url>
  </required_header>
  <id_info>
    <org_study_id>CV013-020</org_study_id>
    <secondary_id>2016-003586-26</secondary_id>
    <nct_id>NCT03357731</nct_id>
  </id_info>
  <brief_title>A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Cross-over Phase 2 Study of Continuous 5-Hour Intravenous Infusions of BMS-986231 in Patients With Heart Failure and Impaired Systolic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of BMS-986231 on systolic and diastolic
      parameters in patients with heart failure and low ejection fraction.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 30, 2017</start_date>
  <completion_date type="Actual">May 10, 2019</completion_date>
  <primary_completion_date type="Actual">May 10, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Stroke Volume Index (SVI) Derived From the Velocity Time Integral at the Left Ventricular Outflow Tract (LVOT VTI) at the End of the 5-hour Infusion of BMS-986231, Versus Placebo</measure>
    <time_frame>at the end of the 5-hour infusion</time_frame>
    <description>The objective is to evaluate the effects of BMS-986231 on the left ventricular (LV) systolic function by stroke volume index (SVI) assessed by echocardiography compared to placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean SVI Derived From LVOT VTI at the End of the 5-hour Infusion of BMS-986231, Versus NTG</measure>
    <time_frame>at the end of the 5-hour infusion</time_frame>
    <description>The objective is to evaluate the effects of BMS-986231 on the left ventricular (LV) systolic function by stroke volume index (SVI) assessed by echocardiography compared to NTG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean LVEF, Computed by Simpson's Method at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG</measure>
    <time_frame>at the end of the 5-hour infusion</time_frame>
    <description>Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:
LV ejection fraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Cardiac Power Index at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG</measure>
    <time_frame>at the end of the 5-hour infusion</time_frame>
    <description>Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:
Mean LV power index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Diastolic Indices: E/A and E/e' Ratio at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG</measure>
    <time_frame>at the end of the 5-hour infusion</time_frame>
    <description>Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:
Diastolic function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Diastolic Indices: Annular e' Velocity at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG</measure>
    <time_frame>at the end of the 5-hour infusion</time_frame>
    <description>Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:
Diastolic function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean LV Global Longitudinal Strain, Computed Using STE at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG</measure>
    <time_frame>at the end of the 5-hour infusion</time_frame>
    <description>Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:
LV global longitudinal strain</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Heart Failure</condition>
  <condition>Cardiac Failure</condition>
  <condition>Reduced Ventricular Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Placebo/BMS-986231/NTG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/NTG/BMS-986231</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NTG/Placebo/BMS-986231</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NTG/BMS-986231/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-986231/Placebo/NTG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-986231/NTG/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HNO Donor</intervention_name>
    <description>Infusion</description>
    <arm_group_label>BMS-986231/NTG/Placebo</arm_group_label>
    <arm_group_label>BMS-986231/Placebo/NTG</arm_group_label>
    <arm_group_label>NTG/BMS-986231/Placebo</arm_group_label>
    <arm_group_label>NTG/Placebo/BMS-986231</arm_group_label>
    <arm_group_label>Placebo/BMS-986231/NTG</arm_group_label>
    <arm_group_label>Placebo/NTG/BMS-986231</arm_group_label>
    <other_name>BMS-986231</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitroglycerin (NTG)</intervention_name>
    <description>Infusion</description>
    <arm_group_label>BMS-986231/NTG/Placebo</arm_group_label>
    <arm_group_label>BMS-986231/Placebo/NTG</arm_group_label>
    <arm_group_label>NTG/BMS-986231/Placebo</arm_group_label>
    <arm_group_label>NTG/Placebo/BMS-986231</arm_group_label>
    <arm_group_label>Placebo/BMS-986231/NTG</arm_group_label>
    <arm_group_label>Placebo/NTG/BMS-986231</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Infusion</description>
    <arm_group_label>BMS-986231/NTG/Placebo</arm_group_label>
    <arm_group_label>BMS-986231/Placebo/NTG</arm_group_label>
    <arm_group_label>NTG/BMS-986231/Placebo</arm_group_label>
    <arm_group_label>NTG/Placebo/BMS-986231</arm_group_label>
    <arm_group_label>Placebo/BMS-986231/NTG</arm_group_label>
    <arm_group_label>Placebo/NTG/BMS-986231</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Heart failure with reduced ejection fraction (LVEF on echocardiogram of 40% or less)

          -  Stable guideline directed therapy for heart failure including oral diuretics, ACEi,
             ARBs, ARNi, MRAs, and β blockers as tolerated, with no dose changes of these
             medications in the past 2 weeks

          -  Have screening values of NT pro-BNP ≥ 125 pg/mL (15 pmol/L) or BNP ≥ 35 pg/mL (10
             pmol/L)

        Exclusion Criteria:

          -  Systolic blood pressure (SBP) &lt; 110 mm Hg at screening or pre-randomization

          -  Heart rate &lt; 50 beats per minute (bpm) or &gt; 90 bpm at screening or pre-randomization

          -  Permanent Atrial Fibrillation, Atrial Flutter or having Atrial Fibrillation, Atrial
             Flutter

          -  Estimated glomerular filtration rate (eGFR) &lt; 15 ml/min/1.73 m2

          -  Ventricular assist device or prior heart transplant

          -  Prior solid organ transplant

          -  Body weight &lt; 45 kg or ≥ 140 kg

          -  Low quality echocardiographic visualization windows and image acquisition

          -  Permanent paced rhythm (VVI, DDD or BiV pacing)

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine-Indianapolis</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-1218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Womens Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Advanced Heart and Lung Failure Clinic</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Heart and Vascular Institute</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <zip>211-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Suita-shi</city>
        <state>Osaka</state>
        <zip>5650871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Groiningen</city>
        <zip>9713GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Glasgow</city>
        <zip>G4 0SF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Glasgow</city>
        <zip>G429LF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Harrow</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>London</city>
        <zip>SE1 1YR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>London</city>
        <zip>sw17 0re</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 31, 2017</study_first_submitted>
  <study_first_submitted_qc>November 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2017</study_first_posted>
  <results_first_submitted>May 6, 2020</results_first_submitted>
  <results_first_submitted_qc>May 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 29, 2020</results_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroglycerin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 6, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT03357731/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 24, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT03357731/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>49 participants assigned to treatment and 45 treated. Reasons not treated: 2 re-randomized; 1 randomized in error, screen failure; 1 no longer met study criteria.
Note: Study designed for all participants to enter all 3 arms (reassignment of arms occurs every period change).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1</title>
          <description>Participants crossed-over from one therapy to the next following Day 1 treatment and a minimum 5-day washout period.
3 treatments were given via 1 of 6 different order sequences across 3 total treatment periods, 1 treatment per period. Treatments were as follows: Placebo (PBO) BMS-986231 (drug) Nitroglycerin (NTG)
Sequence of treatment for this group is as follows: PBO-drug-NTG</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2</title>
          <description>Participants crossed-over from one therapy to the next following Day 1 treatment and a minimum 5-day washout period.
3 treatments were given via 1 of 6 different order sequences across 3 total treatment periods, 1 treatment per period. Treatments were as follows: Placebo (PBO) BMS-986231 (drug) Nitroglycerin (NTG)
Sequence of treatment for this group is as follows: PBO-NTG-drug</description>
        </group>
        <group group_id="P3">
          <title>Sequence 3</title>
          <description>Participants crossed-over from one therapy to the next following Day 1 treatment and a minimum 5-day washout period.
3 treatments were given via 1 of 6 different order sequences across 3 total treatment periods, 1 treatment per period. Treatments were as follows: Placebo (PBO) BMS-986231 (drug) Nitroglycerin (NTG)
Sequence of treatment for this group is as follows: NTG-PBO-drug</description>
        </group>
        <group group_id="P4">
          <title>Sequence 4</title>
          <description>Participants crossed-over from one therapy to the next following Day 1 treatment and a minimum 5-day washout period.
3 treatments were given via 1 of 6 different order sequences across 3 total treatment periods, 1 treatment per period. Treatments were as follows: Placebo (PBO) BMS-986231 (drug) Nitroglycerin (NTG)
Sequence of treatment for this group is as follows: NTG-drug-PBO</description>
        </group>
        <group group_id="P5">
          <title>Sequence 5</title>
          <description>Participants crossed-over from one therapy to the next following Day 1 treatment and a minimum 5-day washout period.
3 treatments were given via 1 of 6 different order sequences across 3 total treatment periods, 1 treatment per period. Treatments were as follows: Placebo (PBO) BMS-986231 (drug) Nitroglycerin (NTG)
Sequence of treatment for this group is as follows: drug-PBO-NTG</description>
        </group>
        <group group_id="P6">
          <title>Sequence 6</title>
          <description>Participants crossed-over from one therapy to the next following Day 1 treatment and a minimum 5-day washout period.
3 treatments were given via 1 of 6 different order sequences across 3 total treatment periods, 1 treatment per period. Treatments were as follows: Placebo (PBO) BMS-986231 (drug) Nitroglycerin (NTG)
Sequence of treatment for this group is as follows: drug-NTG-PBO</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Period 1 (P1)</title>
              <participants_list>
                <participants group_id="P1" count="8">1 withdrew post-P1 completion/prior to P2 therapy due to acute cholecystitis, but returned for P2/P3</participants>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6">1 discontinued P1 due to acute bradycardia and hypotension</participants>
                <participants group_id="P5" count="7">1 discontinued P1 due to hypotension but resumed P2/P3</participants>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Period 2 (P2)</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="4">1 completed P1, did not proceed to P2/P3 (lost to follow-up);
1 discontinued P2 due to hypotension</participants>
                <participants group_id="P5" count="7">1 only completed P1, did not continue to P2/P3 (withdrew consent due to personal reasons)</participants>
                <participants group_id="P6" count="7">1 discontinued P2 due to an Adverse Event (AE)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6">1 discontinuation due to hypotension</participants>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrew consent due to personal reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Acute bradycardia and hypotension</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hypotension</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Participants</title>
          <description>Inclusive of all treatments, all periods. Note: Participants crossed-over from either placebo, drug or NTG arm to the next (in various sequence) following Day 1 treatment and a minimum 5-day washout period, per arm.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.7" spread="12.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Stroke Volume Index (SVI) Derived From the Velocity Time Integral at the Left Ventricular Outflow Tract (LVOT VTI) at the End of the 5-hour Infusion of BMS-986231, Versus Placebo</title>
        <description>The objective is to evaluate the effects of BMS-986231 on the left ventricular (LV) systolic function by stroke volume index (SVI) assessed by echocardiography compared to placebo.</description>
        <time_frame>at the end of the 5-hour infusion</time_frame>
        <population>Intent to Treat (ITT) population: All randomized participants who started study drug infusion in at least one treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO)</title>
            <description>Placebo-matching treatment. Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.
Treatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:
PBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO</description>
          </group>
          <group group_id="O2">
            <title>BMS-986231</title>
            <description>BMS-986231: 3 μg/kg/min for 10 min, followed by 6 μg/kg/min for 10 min, followed by 12 μg/kg/min for the rest of the 5-hour infusion.
Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.
Treatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:
PBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO</description>
          </group>
          <group group_id="O3">
            <title>Nitroglycerin (NTG)</title>
            <description>NTG: 20 μg/min for 10 min, followed by 40 μg/min for 10 min, followed by 80 μg/min for the rest of the 5-hour infusion Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.
Treatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:
PBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Stroke Volume Index (SVI) Derived From the Velocity Time Integral at the Left Ventricular Outflow Tract (LVOT VTI) at the End of the 5-hour Infusion of BMS-986231, Versus Placebo</title>
          <description>The objective is to evaluate the effects of BMS-986231 on the left ventricular (LV) systolic function by stroke volume index (SVI) assessed by echocardiography compared to placebo.</description>
          <population>Intent to Treat (ITT) population: All randomized participants who started study drug infusion in at least one treatment period.</population>
          <units>mL/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.545" spread="7.0243"/>
                    <measurement group_id="O2" value="28.721" spread="9.0174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.027</p_value>
            <method>Kenward-Roger degree of freedom</method>
            <method_desc>Kenward-Roger degree of freedom is used to adjust the standard error of treatment effect</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.150</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9242</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.0432</ci_lower_limit>
            <ci_upper_limit>-0.2570</ci_upper_limit>
            <estimate_desc>The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean SVI Derived From LVOT VTI at the End of the 5-hour Infusion of BMS-986231, Versus NTG</title>
        <description>The objective is to evaluate the effects of BMS-986231 on the left ventricular (LV) systolic function by stroke volume index (SVI) assessed by echocardiography compared to NTG.</description>
        <time_frame>at the end of the 5-hour infusion</time_frame>
        <population>Intent to Treat (ITT) population: All randomized participants who started study drug infusion in at least one treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO)</title>
            <description>Placebo-matching treatment. Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.
Treatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:
PBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO</description>
          </group>
          <group group_id="O2">
            <title>BMS-986231</title>
            <description>BMS-986231: 3 μg/kg/min for 10 min, followed by 6 μg/kg/min for 10 min, followed by 12 μg/kg/min for the rest of the 5-hour infusion.
Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.
Treatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:
PBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO</description>
          </group>
          <group group_id="O3">
            <title>Nitroglycerin (NTG)</title>
            <description>NTG: 20 μg/min for 10 min, followed by 40 μg/min for 10 min, followed by 80 μg/min for the rest of the 5-hour infusion Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.
Treatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:
PBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO</description>
          </group>
        </group_list>
        <measure>
          <title>Mean SVI Derived From LVOT VTI at the End of the 5-hour Infusion of BMS-986231, Versus NTG</title>
          <description>The objective is to evaluate the effects of BMS-986231 on the left ventricular (LV) systolic function by stroke volume index (SVI) assessed by echocardiography compared to NTG.</description>
          <population>Intent to Treat (ITT) population: All randomized participants who started study drug infusion in at least one treatment period.</population>
          <units>mL/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="28.721" spread="9.0174"/>
                    <measurement group_id="O3" value="27.811" spread="7.9712"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.846</p_value>
            <method>Kenward-Roger degree of freedom</method>
            <method_desc>Kenward-Roger degree of freedom is used to adjust the standard error of treatment effect</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.193</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9832</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8176</ci_lower_limit>
            <ci_upper_limit>2.2042</ci_upper_limit>
            <estimate_desc>The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean LVEF, Computed by Simpson's Method at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG</title>
        <description>Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:
LV ejection fraction</description>
        <time_frame>at the end of the 5-hour infusion</time_frame>
        <population>Intent to Treat (ITT) population: All randomized participants who started study drug infusion in at least one treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO)</title>
            <description>Placebo-matching treatment. Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.
Treatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:
PBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO</description>
          </group>
          <group group_id="O2">
            <title>BMS-986231</title>
            <description>BMS-986231: 3 μg/kg/min for 10 min, followed by 6 μg/kg/min for 10 min, followed by 12 μg/kg/min for the rest of the 5-hour infusion.
Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.
Treatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:
PBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO</description>
          </group>
          <group group_id="O3">
            <title>Nitroglycerin (NTG)</title>
            <description>NTG: 20 μg/min for 10 min, followed by 40 μg/min for 10 min, followed by 80 μg/min for the rest of the 5-hour infusion Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.
Treatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:
PBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO</description>
          </group>
        </group_list>
        <measure>
          <title>Mean LVEF, Computed by Simpson's Method at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG</title>
          <description>Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:
LV ejection fraction</description>
          <population>Intent to Treat (ITT) population: All randomized participants who started study drug infusion in at least one treatment period.</population>
          <units>Percentage of blood pumped from the LV</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.9" spread="7.15"/>
                    <measurement group_id="O2" value="32.8" spread="8.24"/>
                    <measurement group_id="O3" value="33.5" spread="7.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.177</p_value>
            <method>Kenward-Roger degree of freedom</method>
            <method_desc>Kenward-Roger degree of freedom is used to adjust the standard error of treatment effect</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.93</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.62</ci_lower_limit>
            <ci_upper_limit>3.19</ci_upper_limit>
            <estimate_desc>The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.839</p_value>
            <method>Kenward-Roger degree of freedom</method>
            <method_desc>Kenward-Roger degree of freedom is used to adjust the standard error of treatment effect</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.48</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.08</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
            <estimate_desc>The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Cardiac Power Index at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG</title>
        <description>Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:
Mean LV power index</description>
        <time_frame>at the end of the 5-hour infusion</time_frame>
        <population>Intent to Treat (ITT) population: All randomized participants who started study drug infusion in at least one treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO)</title>
            <description>Placebo-matching treatment. Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.
Treatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:
PBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO</description>
          </group>
          <group group_id="O2">
            <title>BMS-986231</title>
            <description>BMS-986231: 3 μg/kg/min for 10 min, followed by 6 μg/kg/min for 10 min, followed by 12 μg/kg/min for the rest of the 5-hour infusion.
Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.
Treatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:
PBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO</description>
          </group>
          <group group_id="O3">
            <title>Nitroglycerin (NTG)</title>
            <description>NTG: 20 μg/min for 10 min, followed by 40 μg/min for 10 min, followed by 80 μg/min for the rest of the 5-hour infusion Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.
Treatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:
PBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Cardiac Power Index at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG</title>
          <description>Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:
Mean LV power index</description>
          <population>Intent to Treat (ITT) population: All randomized participants who started study drug infusion in at least one treatment period.</population>
          <units>watts per square meter (W/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4122" spread="0.14404"/>
                    <measurement group_id="O2" value="0.3427" spread="0.10463"/>
                    <measurement group_id="O3" value="0.3568" spread="0.09184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Kenward-Roger degree of freedom</method>
            <method_desc>Kenward-Roger degree of freedom is used to adjust the standard error of treatment effect</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.0977</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03308</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.16634</ci_lower_limit>
            <ci_upper_limit>-0.02915</ci_upper_limit>
            <estimate_desc>The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.103</p_value>
            <method>Kenward-Roger degree of freedom</method>
            <method_desc>Kenward-Roger degree of freedom is used to adjust the standard error of treatment effect</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.0371</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02194</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.08243</ci_lower_limit>
            <ci_upper_limit>0.00814</ci_upper_limit>
            <estimate_desc>The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Diastolic Indices: E/A and E/e' Ratio at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG</title>
        <description>Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:
Diastolic function</description>
        <time_frame>at the end of the 5-hour infusion</time_frame>
        <population>Intent to Treat (ITT) population: All randomized participants who started study drug infusion in at least one treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO)</title>
            <description>Placebo-matching treatment. Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.
Treatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:
PBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO</description>
          </group>
          <group group_id="O2">
            <title>BMS-986231</title>
            <description>BMS-986231: 3 μg/kg/min for 10 min, followed by 6 μg/kg/min for 10 min, followed by 12 μg/kg/min for the rest of the 5-hour infusion.
Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.
Treatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:
PBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO</description>
          </group>
          <group group_id="O3">
            <title>Nitroglycerin (NTG)</title>
            <description>NTG: 20 μg/min for 10 min, followed by 40 μg/min for 10 min, followed by 80 μg/min for the rest of the 5-hour infusion Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.
Treatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:
PBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Diastolic Indices: E/A and E/e' Ratio at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG</title>
          <description>Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:
Diastolic function</description>
          <population>Intent to Treat (ITT) population: All randomized participants who started study drug infusion in at least one treatment period.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>E/A ratio</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="0.278"/>
                    <measurement group_id="O2" value="0.73" spread="0.270"/>
                    <measurement group_id="O3" value="0.71" spread="0.310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>E/e' ratio</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.42" spread="4.102"/>
                    <measurement group_id="O2" value="7.00" spread="2.464"/>
                    <measurement group_id="O3" value="7.81" spread="2.652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>E/A ratio</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Kenward-Roger degree of freedom</method>
            <method_desc>Kenward-Roger degree of freedom is used to adjust the standard error of treatment effect</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.037</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.205</ci_lower_limit>
            <ci_upper_limit>-0.051</ci_upper_limit>
            <estimate_desc>The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>E/A ratio</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.904</p_value>
            <method>Kenward-Roger degree of freedom</method>
            <method_desc>Kenward-Roger degree of freedom is used to adjust the standard error of treatment effect</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.051</ci_lower_limit>
            <ci_upper_limit>0.057</ci_upper_limit>
            <estimate_desc>The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>E/e' ratio</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Kenward-Roger degree of freedom</method>
            <method_desc>Kenward-Roger degree of freedom is used to adjust the standard error of treatment effect</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.66</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.527</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.763</ci_lower_limit>
            <ci_upper_limit>-0.549</ci_upper_limit>
            <estimate_desc>The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>E/e' ratio</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.503</p_value>
            <method>Kenward-Roger degree of freedom</method>
            <method_desc>Kenward-Roger degree of freedom is used to adjust the standard error of treatment effect</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.392</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.085</ci_lower_limit>
            <ci_upper_limit>0.550</ci_upper_limit>
            <estimate_desc>The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Diastolic Indices: Annular e' Velocity at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG</title>
        <description>Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:
Diastolic function</description>
        <time_frame>at the end of the 5-hour infusion</time_frame>
        <population>Intent to Treat (ITT) population: All randomized participants who started study drug infusion in at least one treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO)</title>
            <description>Placebo-matching treatment. Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.
Treatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:
PBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO</description>
          </group>
          <group group_id="O2">
            <title>BMS-986231</title>
            <description>BMS-986231: 3 μg/kg/min for 10 min, followed by 6 μg/kg/min for 10 min, followed by 12 μg/kg/min for the rest of the 5-hour infusion.
Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.
Treatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:
PBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO</description>
          </group>
          <group group_id="O3">
            <title>Nitroglycerin (NTG)</title>
            <description>NTG: 20 μg/min for 10 min, followed by 40 μg/min for 10 min, followed by 80 μg/min for the rest of the 5-hour infusion Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.
Treatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:
PBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Diastolic Indices: Annular e' Velocity at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG</title>
          <description>Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:
Diastolic function</description>
          <population>Intent to Treat (ITT) population: All randomized participants who started study drug infusion in at least one treatment period.</population>
          <units>cm/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.18" spread="2.467"/>
                    <measurement group_id="O2" value="8.07" spread="2.333"/>
                    <measurement group_id="O3" value="7.18" spread="2.143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>annular e’ velocity</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.994</p_value>
            <method>Kenward-Roger degree of freedom</method>
            <method_desc>Kenward-Roger degree of freedom is used to adjust the standard error of treatment effect</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.398</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.827</ci_lower_limit>
            <ci_upper_limit>0.820</ci_upper_limit>
            <estimate_desc>The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>annular e’ velocity</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.073</p_value>
            <method>Kenward-Roger degree of freedom</method>
            <method_desc>Kenward-Roger degree of freedom is used to adjust the standard error of treatment effect</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.258</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.049</ci_lower_limit>
            <ci_upper_limit>1.013</ci_upper_limit>
            <estimate_desc>The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean LV Global Longitudinal Strain, Computed Using STE at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG</title>
        <description>Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:
LV global longitudinal strain</description>
        <time_frame>at the end of the 5-hour infusion</time_frame>
        <population>Intent to Treat (ITT) population: All randomized participants who started study drug infusion in at least one treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO)</title>
            <description>Placebo-matching treatment. Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.
Treatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:
PBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO</description>
          </group>
          <group group_id="O2">
            <title>BMS-986231</title>
            <description>BMS-986231: 3 μg/kg/min for 10 min, followed by 6 μg/kg/min for 10 min, followed by 12 μg/kg/min for the rest of the 5-hour infusion.
Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.
Treatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:
PBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO</description>
          </group>
          <group group_id="O3">
            <title>Nitroglycerin (NTG)</title>
            <description>NTG: 20 μg/min for 10 min, followed by 40 μg/min for 10 min, followed by 80 μg/min for the rest of the 5-hour infusion Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.
Treatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:
PBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO</description>
          </group>
        </group_list>
        <measure>
          <title>Mean LV Global Longitudinal Strain, Computed Using STE at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG</title>
          <description>Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:
LV global longitudinal strain</description>
          <population>Intent to Treat (ITT) population: All randomized participants who started study drug infusion in at least one treatment period.</population>
          <units>Percentage of blood pumped from the LV</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.98" spread="2.860"/>
                    <measurement group_id="O2" value="-11.94" spread="3.458"/>
                    <measurement group_id="O3" value="-11.36" spread="3.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.705</p_value>
            <method>Kenward-Roger degree of freedom</method>
            <method_desc>Kenward-Roger degree of freedom is used to adjust the standard error of treatment effect</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.400</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.670</ci_lower_limit>
            <ci_upper_limit>0.976</ci_upper_limit>
            <estimate_desc>The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.105</p_value>
            <method>Kenward-Roger degree of freedom</method>
            <method_desc>Kenward-Roger degree of freedom is used to adjust the standard error of treatment effect</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.68</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.404</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.504</ci_lower_limit>
            <ci_upper_limit>0.151</ci_upper_limit>
            <estimate_desc>The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose to 30 days post last dose (approximately 3 months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo (PBO)</title>
          <description>Placebo-matching treatment. Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.
Treatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:
PBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO</description>
        </group>
        <group group_id="E2">
          <title>BMS-986231</title>
          <description>BMS-986231: 3 μg/kg/min for 10 min, followed by 6 μg/kg/min for 10 min, followed by 12 μg/kg/min for the rest of the 5-hour infusion.
Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.
Treatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:
PBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO</description>
        </group>
        <group group_id="E3">
          <title>Nitroglycerin (NTG)</title>
          <description>NTG: 20 μg/min for 10 min, followed by 40 μg/min for 10 min, followed by 80 μg/min for the rest of the 5-hour infusion Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.
Treatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:
PBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bristol-Myers Squibb Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <phone>Please email:</phone>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

